MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
MAXCYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.30+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.31 (−19.25%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MAXCYTE, INC. saw revenue fall 13.2% to $31.05M over the twelve months to Jun 30, 2026. Free cash flow was -$23.64M.
Revenue
$31.05M
-13.2% vs. a year earlier
Operating income
-$41.79M
TTM Q2 2026
Free cash flow
-$23.64M
TTM Q2 2026
EPS, diluted
-$0.33
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $138.87M
- P/E ratio
- –
- Price to sales
- 4.47
- Price to book
- 0.87
- Dividend yield
- –
- Free cash flow yield
- -17.02%
Fundamentals
- Revenue
- $31.05M
- Net income
- -$35.64M
- EPS, diluted
- -$0.33
- Free cash flow
- -$23.64M
- Book value per share
- $1.49
- Diluted shares
- 107M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$31.05M-13.2% YoY
Gross profit
$24.60M-13.8% YoY
Operating income
-$41.79M
Net income
-$35.64M
EPS, diluted
-$0.33
Free cash flow
-$23.64M
Reported periodTrailing twelve months